The REMS for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been eliminated because the FDA has determined that a REMS is no longer necessary.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/fZGCFrY
No comments:
Post a Comment